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ABSTRACT
After brieﬂy discussing endothelial glycocalyx and its role in
vascular physiology and renal disease, this overview focuses on
its degradation very early in the course of microbial sepsis. We
describe our recently proposed mechanism for glycocalyx deg-
radation induced by exocytosis of lysosome-related organelles
and release of their cargo. Notably, an intermediate in nitric
oxide synthesis, NG-hydroxy-l-arginine, shows efﬁcacy in cur-
tailing exocytosis of these organelles and improvement in ani-
mal survival. These data not only depict a novel mechanism
responsible for very early glycocalyx degradation, but may also
outline a potential preventive therapy. The second issue dis-
cussed in this article is related to the therapeutic acceleration of
restoration of already degraded endothelial glycocalyx. Here,
using as an example our recent ﬁndings obtained with sulodex-
ide, we illustrate the importance of the expedited repair of
degraded endothelial glycocalyx for the survival of animals with
severe sepsis. These two focal points of the review on glycocalyx
may not only have broader disease applicability, but they may
also provide additional evidence to buttress the idea of the
importance of endothelial glycocalyx and its maintenance and
repair in the prevention and treatment of an array of renal and
nonrenal diseases.
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INTRODUCTION
Sepsis is defined as a systemic inflammatory syndrome
induced by bacterial infection that can lead to multiorgan
failure. It afflicts>750 000 people annually in the USA alone
and has mortality rates of 28–50%. Even a few percentage
points in improved survival would account for a large salu-
tary net effect. One of the key molecular causes of Gram-
negative septicemia is endotoxin consisting of lipopolysac-
charides (LPSs) bound with high affinity to LPS-binding
glycoprotein (LPS-LBP). Complex LPS-LBP is recognized
by pattern recognition receptors, like its cognate receptor
TLR4 and a coreceptor CD14 expressed on monocytes/mac-
rophages and endothelial cells [1]. Gram-positive bacterial
superantigens and bacterial wall products peptidoglycan
and lipoteichoic acids induce sepsis which is clinically indis-
tinguishable from Gram-negative bacteria due to the
involvement of similar receptors/mediators (TLR2).
Considering the systemic nature of septicemia, vascular
endothelium represents the first line of exposure to bacterial
endotoxins [2]. It responds to endotoxins with a complex
system of ‘danger signals’, which are chronologically
sequenced and spatially propagating [3]. Functionally, these
waves of danger signaling tend to secure proper organismal
responses, both pro- and anti-inflammatory.
VASCULATURE-RELATED COMPLICATIONS
OF SEPSIS COMPRISE THE MAJOR PART OF
CLINICAL MANIFESTATIONS
One of the hallmarks of circulation in severe sepsis accompa-
nied by the decline in blood pressure is the redistribution of
blood flow to vital organs, like the brain and heart, stealing it
from other organs. In humans with sepsis and acute kidney
injury (AKI), renal blood flow is reduced [4]. The dynamics of
renal blood flow in less severe forms of sepsis are inconsistent.
More important, however, is the impairment of renal microcir-
culation in sepsis [5, 6], of which endothelial glycocalyx (EG) is||
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an early victim [7–9]. Its degradation is believed to contribute to
the symptomatology of sepsis, as will be elaborated below.
EG: STRUCTURE AND FUNCTIONS
The endothelial cell surface is coated with a carbohydrate-rich
layer with an average thickness of 0.1 to  2 mm and consisting
of hyaluronic acid (HA) cords reaching 1 mm in length and
heparan sulfate (HS) chains reaching 200 nm in length and
comprising 50–90% of endothelial glycosaminoglycans, with an
admixture of dermatan, keratan and chondroitin sulfates
(reviewed in [10]). The high degree of sulfation of these compo-
nents provides EG with a net negative charge. The membrane-
tethered scaffold for these glycosaminoglycans consists of two
families of proteoglycans: syndecans 1–4 (single membrane-
spanning domain) and glypicans 1–6 (glycosylphosphatidylino-
sitol-anchored). HA, on the other hand, binds to osteopontin
receptor CD44 (Figure 1A). In addition, several glycoprotein
families (selectins, integrins and immunoglobulins) are present
in EG and their expression is induced by pro-inflammatory
stimuli. EG provides a repository for diverse biologically active
molecules, as it incorporates and interacts with extracellular
superoxide dismutase (SOD), xanthine oxidoreductase, several
interleukins [(ILs), including IL-2–IL-5, IL-7, IL-8 and IL-12],
low-density lipoprotein (LDL) and LDL lipase, fibroblast
growth factor, vascular endothelium growth factor, transform-
ing growth factor b and several regulators of coagulation (such
as antithrombin III, heparin cofactor II and tissue pathway fac-
tor inhibitor) [10].
Due to its unique location, this structure provides a passive
barrier to water and solute transport (regulation of vascular per-
meability) and to the interaction between circulating cells and
endothelial cells (regulation of leukocyte trafficking). It also
serves as a sensor of mechanical forces, such as shear stress and
pressure, and shields cell surface receptors, preventing their
hyperactivation [11, 12]. However, this structure is quite vulner-
able and tends to disintegrate under the influence of various
stressors, such as endotoxins, ischemia/hypoxia/reperfusion
and oxidative stress, among others. It also leads to
hyperactivation of plasma membrane receptors left exposed to
respective unhindered ligands, with further activation of endo-
thelial cells and propagation of danger signaling. The degrada-
tion of EG is also accompanied by compromised anticoagulant
properties of this layer, increased endothelial permeability,
reduced antioxidant barrier, enhanced transmigration of pro-
inflammatory cells, impaired mechanotransduction and endo-
thelial nitric oxide synthase activity.
Glycocalyx remains poorly studied due to difficulties in pre-
serving its structure upon tissue fixation and the limited
A B
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Hyaluronidase Sheddases
FIGURE 1: Scenarios for degradation of EG. (A) A simpliﬁed schema of EG. HA (orange); heparan sulfate (red; dermatan and chondroitin sul-
fates are not shown for clarity). Note that diverse proteins are nested in EG, as those shown, as well as albumin and others (see text). GF,
growth factors. (B) Heparanase-induced fragmentation of HS results in a partial degradation of EG. (C) Hyaluronidase-induced breakdown of
HA chains results in a partial degradation of EG and an increase in permeability. (D) Sheddases cleave proteoglycans, syndecans and glypicans,
resulting in peeling off of the entire EG structure. It should be noted that derangements in each component of EG lead in time to disorganiza-
tion of other components. Hence, the schema depicts only the initial action of EG-degrading enzymes. Nonetheless, this latter scenario based
on the action of sheddases results in a most severe and complete degradation of EG (akin to opening a can).
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number of experimental tools for its visualization. Therefore,
there is no confidently charted time course of damage and dis-
integration for EG. Some studies detect these changes at 6 h
post-insult, others at 20min [13, 14]. Yet, the precise chronol-
ogy of the loss of EG is of critical significance, as it determines
whether and to what extent the loss of glycocalyx is involved in
the early pathogenic steps of systemic inflammatory response,
its maintenance, or both. Our recent use of stochastic optical
reconstruction microscopy (STORM) has made it possible to
visualize this structure at high resolution and lend support to
the idea that EG is degraded very early in the course of a sepsis
model.
STORM employs organic dyes and fluorescent proteins as
photoswitchable emitters to trade temporal resolution for a
super spatial resolution (20nm lateral and 50nm axial at
present), which is an order of magnitude greater than conven-
tional confocal microscopy. In addition, atomic force micro-
scopy (AFM), in accordance with the Oberleithner’s pioneering
work [9], offers an ex vivo tool to study EG, as briefly detailed
below. We have performed AFM nanoindentation on living
human umbilical vein endothelial cells (HUVECs), as schemati-
cally detailed in Figure 2. Light microscopy was used to ensure
that the AFM tip was located neither at the nuclear nor at the
junctional region of cultured ECs. In some experiments, the
cells were stained with wheat germ agglutinin-fluorescein
isothiocyanate (FITC) to simultaneously monitor the intactness
of EG (Figure 2B, insets). During the indentation scan, the AFM
tip travels vertically towards the cell surface. Upon indentation
of the EG, the AFM cantilever, serving as a soft spring, is
deflected (boxed region in Figure 2B, upper panel). The cantile-
ver deflection is measured and plotted as a function of the sam-
ple position along the z-axis. The resulting curve is transformed
into a force-versus-indentation curve using the cantilever’s
spring constant and the light lever sensitivity. The slope of a
force indentation curve directly reflects the stiffness (expressed
in pN/nm), which is necessary to indent the EG for a certain
distance. The first slope indicates the stiffness (in this trace 0.30
pN/nm) of the very first layer encountered by the cantilever,
which is the EG. The second nonlinear region indicates the
stiffness of the plasma membrane. In agreement with studies
from Oberleithner’s group [9, 15], we found that EG behaves as
a linear spring, resulting in a single fixed stiffness value. The dis-
tance between the starting point of EG indentation and the
starting point of the second slope (projected to the x-axis) corre-
sponds to the thickness of the EG (in this trace 550 nm). On
average, EG on HUVECs has a thickness of 6516 54nm and a
stiffness of 0.25 6 0.07 pN/nm. Treatment of HUVECs with
heparanases I and III eliminates the linear spring region of the
force-indentation curve, indicating that the EG is degraded by
enzymatic digestion.
VERY EARLY EVENTS IN SEPSIS :
STRESS- INDUCED EXOCYTOSIS OF
LYSOSOME-RELATED ORGANELLES
AND PATCHY LOSS OF EG
Damage to and loss of EG have been observed in many diseases,
including diabetes, ischemia, myocardial infarction, chronic
infections, atherosclerosis and tumor metastases, among others
[10, 11, 16, 17]. The disintegration of this structure predisposes to
leukocyte adhesion, emigration and tissue infiltration by poly-
morphonuclear leukocytes, monocyte/macrophages and lympho-
cytes. Degradation of EG at the sites of exocytosis of lysosome-
related organelles occurs very early in sepsis, as detailed below.
The mechanisms responsible for the loss of EG have not
been exhaustively studied. Two scenarios have been proposed.
Schmidt et al. [13] proposed that its shedding occurs as a result
of liberation of heparanase. These studies, in our view, disclose
one part of the problem, namely degradation of heparan sulfate
moieties, which have been shown [18] to be dispensable for the
maintenance of the barrier properties of EG. Annecke et al. [14]
proposed that the loss of EG is initiated by the purine
metabolites–induced degranulation of resident mast cells and
release of tryptase b acting as a sheddase. The instantaneous
dilution of tryptase b in the bloodstream would, however,
reduce the impact of this factor on EG. Hence, though elegant
and convincing, neither explanation appears to be overarching.
FIGURE 2: AFM nanoindentation. (A) A schematic diagram of the AFM assay. Insert: a picture of the AFM head used for nanoindentation.
The blue layer on the cell surface indicates the ESG. (B) Quantiﬁcation of the thickness and stiffness of EG by AFM nanoindentation.
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|Among the earliest responses of endothelial cells to stress-
ful activators are exocytosis of Weibel–Palade bodies (WPBs)
and secretory lysosomes [19]. WPBs are rod-shaped organelles
(0.2 2–3 mm in size) characteristic to endothelial cells and
containing an array of proteins, peptides and cytokines,
which can be released emergently on demand. Among these
biologically active compounds are von Willebrand factor
(vWF), P-selectin, IL-8, endothelin 1 and its converting
enzyme, angiopoietin 2, fucosyltransferrase and others, which
contribute to the induction of a pro-inflammatory milieu on
the one hand, but also induce mobilization of stem cells on the
other. A list of compounds known to induce exocytosis of
WPBs includes thrombin, histamine, peptido-leukotrienes,
complement components, superoxide anion, vascular endo-
thelial growth factor (VEGF), sphingosine-1-phosphate,
ceramide, purine nucleotides, serotonin, vasopressin, epi-
nephrine and calcium ionophores [20–22]. The endothelial
lysosomes contain acid/secretory sphingomyelinase, glycohy-
drolases, cathepsins, fucosidase, phosphatases and heparan-
sulfate sulfatase, among others [23].
The mechanisms of exocytosis of lysosome-related organ-
elles, such asWPBs and secretory lysosomes, and release of their
lytic cargo have been partially elucidated. These
‘unconventional secretory pathways’ [24] include organellar
carriers. WPBs or lysosomes dock to the plasma membrane via
the soluble N-ethylmaleimide sensitive factor attachment pro-
tein receptor (SNARE) mechanism, undergo priming and Ca-
dependent fusion with the plasma membrane to release their
cargo [20]. N-ethylmaleimide sensitive factor (NSF) and its
adaptor synaptosome-associated protein (a-SNAP) interact
with SNARE proteins to prime organelles for fusion and/or
recycling. This process can be inhibited by S-nitrosylation of
NSF occurring as a result of nitric oxide action [25]. The b-
helix-loop-helix transcription factor EB that specifically
recognizes E-box sequence 5’-CANNTG-3’ [bHLH-leucine zip-
per transcription factor EB (TFEB)] increases the pool of lyso-
somes in the proximity of the plasma membrane and promotes
their fusion by a calcium-dependent mechanism through acti-
vation of lysosomal non-selective cation channel mucolipin-1
(MCOLN 1) [26]. Another source of LPS-induced elevated cal-
cium in endothelial cells is a stromal interaction molecule-1
(STIM-1)-mediated opening of Orai calcium channels and
refilling of the endoplasmic reticulum. Blockade of STIM-1 or
NOX-2 [an NADPH oxidase activated by toll-like receptor 4
(TLR4)] limits LPS-induced vascular inflammation [27]. This
mechanism explains the inhibitory effect of preventing the ele-
vation of intracellular calcium on exocytosis of lysosomes and
WPB. Activation of TFEB has been shown to recruit lysosomal
glycohydrolases b-hexosaminidase and b-galactosidase to the
plasma membrane [28] and cleave oligosaccharide chains of
glycosphingolipids. Matsushita et al. [29] developed fusion pol-
ypeptides composed of a 22-amino acid NSF, a regulator of exo-
cytosis, and a carrier peptide derived from the human
immunodeficiency virus transactivating regulatory protein
domain and demonstrated that inhibition of WPB exocytosis
decreased leukocyte trafficking and peritonitis [30]. N-ethylma-
leimide itself is also a potent inhibitor of exocytosis. de Leeuw
et al. [31] demonstrated that a small GTP-binding protein, Ral,
is involved in exocytosis of WPBs and that expression of a
dominant-negative Ral variant prevented it. More recently,
Bertuglia et al. [32] explored a lysine-proline motif encountered
in several biologically active small peptides and synthesized a
glycine-(Na-Et)lysine-proline-arginine (ITF 1697) peptide,
with a biological half-life of 20–120min, and demonstrated that
it inhibits ischemia–reperfusion-induced exocytosis of WPBs
and protected pulmonary microcirculation by preventing an
increase in permeability, leukocyte and platelet adhesion, P-
selectin and vWF secretion. This peptide has in its core the Lys-
Pro-motif found in tuftsin (a c-globulin-derived peptide stimu-
lator of phagocytosis), a C-terminal region of a-melanocyte-
stimulating hormone endowed with anti-inflammatory proper-
ties and an IL-1b-derived peptide antagonist of hyperalgesic
effect of the parent molecule. We reported the use of ITF 1697
peptide in an ischemia–reperfusion model of renal injury, con-
firmed its inhibitory action on exocytosis of WPBs and demon-
strated that the peptide salvages renal function and morphology
after renal ischemic injury [33]. Importantly, prevention of exo-
cytosis of lysosome-related organelles using nitric oxide inter-
mediate donor NG-hydroxy-L-arginine (NOHA) results in
improved survival in severe experimental sepsis [9].
Based on these studies, we have recently proposed an addi-
tional possible explanation for the stress-induced loss of EG,
namely, that exocytosis of WPBs and secretory lysosomes con-
taining proteolytic, hydrolytic and glycolytic enzymes is respon-
sible for the initiation of EG degradation. We have also
predicted that this exocytotic mechanism could be responsible
for the shedding of syndecans and CD44, further degrading EG.
Specifically, exocytosis of WPBs and lysosomes, both very early
responses of endothelial cells to endotoxin and oxidative stress,
result in the focal degradation of EG, as detected using STORM
[9] (Figure 3 and schema in Figure 4). This very early event
hair-triggers an avalanche of secondary pathological processes,
such as attraction of leukocytes and platelets, thrombosis and
increased vascular permeability. In addition, exocytosed cargo
directly or indirectly (via attracted leukocytes and platelets) acti-
vate a coagulation cascade and sheddases, like disintegrin and
metalloproteinase domain-containing-17 (ADAM-17), thus
potentially leading to shedding of CD44 and syndecans, critical
structural components of EG (Figure 1B–D). This catapults fur-
ther propagation of EG loss and escalation of septic damage to
the endothelium. The proof of this hypothesis was obtained
through the demonstration of two key facts, namely, (i) that
exocytosis of WPBs and lysosomes does indeed trigger the ini-
tial loss of EG and (ii) that maneuvers directed toward preserva-
tion of EG, such as peptide inhibitors of exocytosis, blockers of
calcium transients, nitric oxide donors and/or hyaluronate-
hydrogel-embedded stem cells, improve the course of sepsis and
overall survival [9].
EG DEGRADATION IN AKI AND DIABETIC
NEPHROPATHY
The above mechanisms of EG degradation are ignited not only
in the initiation of the systemic inflammatory response, like in
sepsis, but they are active in a variety of pathological conditions.
206 J.W. Song et al.
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|In AKI induced by ischemia–reperfusion and/or kidney trans-
plantation, EG is impaired both in experimental animals and in
humans [34–37]. Another most frequent condition associated
with the degradation of EG is diabetic nephropathy. Deckert
et al. [38] observed that the de novo synthesis of heparan sulfate
was reduced in fibroblasts isolated from diabetes patients with
albuminuria, but not from those without albuminuria or
healthy control subjects, and formulated a hypothesis that the
loss of EG is a prerequisite for developing diabetic nephropathy.
Recently, upregulation of endothelin 1 in diabetes was incrimi-
nated in the induction of heparanase in podocytes, resulting in
impairment of glomerular EG [39]. This is in agreement with
studies by different investigators who have demonstrated the
loss of glycocalyx integrity [40–43]. In addition to this, defective
EG is seen in multiple other conditions characterized by endo-
thelial dysfunction. We have recently observed J.W. Song,
unpublished data) that mice with catalytically defective sirtuin
1 in endothelial cells alone, apart from being characterized by
premature vascular senescence, impaired vasorelaxation and
angiogenesis and a propensity towards fibrogenesis, also
exhibit a 50% reduction in the global volume of EG. In fact,
the mechanisms of EG loss, such as oxidative stress or pro-
inflammatory cyto- and chemokines, are highly prevalent in
diverse pathologic states. Under those circumstances, the loss
of EG is not as fulminant as in sepsis, but much more insidi-
ous. This fact explains why preventive measures of EG degra-
dation are insufficient and in clinical practice it would be
more useful to obtain pharmacological tools to facilitate the
restoration of EG.
In all the cases described above, exocytosis of lysosome-
related organelles actuates the initial localized damage to the EG
that exceeds the constitutive recycling of lysosomes and EG.
The localized loss of EG should be reparable under normal con-
ditions. Yet, the pro-inflammatory milieu and persistence of
noxious stimuli aggravate the initial injury to EG and propagate
it to the systemic circulation. These hypothetical scenarios are
schematically depicted in Figure 4.
FACILITATING GLYCOCALYX
RESTORATION
Natural restoration of EG is sluggish. It has previously been
determined that after degradation of EG with either hyaluroni-
dase, heparanase III or tumor necrosis factor a the restoration
of hydrodynamically relevant EG in vivo requires 7 days [44].
Attempts to accelerate EG restoration have been entertained.
Administration of antioxidants, like N-acetylcysteine [45], was
HS vWF HS-vWF side view HS-vWF top 
LP
S-
10
 m
in
   
   
  C
on
tr
ol
FIGURE 3: Representative STORM-acquired images of anti-HS-labeled EG and vWF distribution in controls and 10min after LPS. The panels
show three-dimensional reconstructed images of cultured endothelial cells stained with antibodies against HS and vWF. Note that preparations
were nonpermeabilized so that vWF readily detectable after LPS is located extracellularly. Images display the height of EG and detectability of
vWF in controls and 10min after application of LPS (left panels) and side or top views. Note the readily detectable appearance of vWF 10min
after LPS, where it encroaches into the EG. The sites of detectable vWF also appear to be depleted of HS.
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FIGURE 4: Schematic representation of a very early patchy loss of EG followed by the propagating innate immune response–driven global loss
of EG. Exocytosed cargo molecules are represented in red.
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used to prevent EG shedding during hyperglycemia. However,
considering the fact that SOD is heavily intercalated in the EG,
one is left wondering whether the effects of antioxidants are
really preventive or rather do they act when EG has been
degraded and it endogenous SOD barrier has been lost. An
alternative strategy is represented by systemic use of high
molecular weight HA. Another uses heparan sulfate or its ana-
log, sulodexide (an 8:2 mixture of fast-moving heparin fraction
and dermatan sulfate [46]) to improve EG in diabetes [47]. In
in vitro studies we have tested the efficacy of various compo-
nents of EG restoration and observed a marginal efficacy of HA,
HS or inhibitors of their degradation and improved efficacy of a
cocktail containing all of these compounds (not shown).
However, superior efficacy in restoring EG was observed using
sulodexide. Taking into account the organismal size of the HA
pool (15 g, which is mostly contained on the cell surface and
the extracellular matrix [48, 49]) and the rapidity of its exchange
[50], it is difficult to imagine that HA availability could be a lim-
iting factor for the rate of EG restoration. Yet, studies by Henry
and Duling [48] have demonstrated that supplemental infusion
of HA and chondroitin sulfate accelerates the restoration of EG.
With the serum concentration of HS being >100 mg/ml in
humans [51], it would require significant prior exhaustion of
the pool of HS to account for the salutary effect of supplemental
HS. These arguments should provoke the idea that the restora-
tion of EG is dependent mostly on the activity of enzymes par-
ticipating in its degradation. There are six different
hyaluronidases [52] and their activity is induced in a number of
diseases [53]. Heparanase activity is similarly induced by
inflammatory conditions (reviewed in [54]), which accounts for
the accumulation of HS fragments. The different scenarios of
EG degradation are summarized in Figure 1B–D. While the
degradation of HS and HA alone would appear to result in the
incomplete erasure of EG (Figure 1B and C), the action of shed-
dases results in desquamation of the sheets of EG; these, per-
haps, may be flapping when incompletely detached and float in
the bloodstream when completely detached (Figure 1D).
We hypothesize that superior results of EG restoration could
be achieved by combining components or surrogates of EG
with inhibitors of their respective degradation enzymes—hya-
luronidase and heparanase. Such a prediction is supported by
the rapid kinetics of the basal rate of degradation and sluggish
restoration of EG components. For instance, the rate of hyalur-
onan synthase production of HA approximates 1 molecule/
5min [55] and the entire pool of HA in the body equals 15 g
and is exchanged every 3 days [49]. Only a combination of com-
ponents of EG with hyaluronidase þ heparanase inhibitors
could efficiently accelerate the restoration of EG and its key
components. Unfortunately, there are no inhibitors approved
for humans. There are multiple analogs of commercially avail-
able ()-Epicatechin, a nonselective HA-ase inhibitor. It has
been proposed that a polyketide originating from marine
Streptomyces species, hyaluromycin, is a selective hyaluronidase
inhibitor [56]. On the other hand, PI-88 has been introduced as
a potent inhibitor of heparanase, although its availability to
investigators seems to be quite limited [57]. This leaves
sulodexide, which combines the properties of EG components
with matrix metalloproteinase–inhibitory and heparanase-
inhibitory activities, as the only currently available and
approved compound for clinical use. Its uses in diabetic nephr-
opathy have been described previously [58–60]. Below, we
recount our own experience using sulodexide in mice with poly-
microbial sepsis and loss of EG [61]. For these in vivo studies,
we elected to use the indicators dilution technique, combining
one fluorophore that percolates EG (dextran 40–Texas Red)
with the fluorophore that does not percolate (dextran 500–
FITC). We elected the soilage model of polymicrobial sepsis
and showed that sulodexide treatment instituted after the
induction of sepsis results in a significantly improved restora-
tion of EG (Figure 5), both using the volume of distribution flu-
orophore dilution technique and en face aorta staining. In these
experiments, sulodexide administered 2 h after induction
of sepsis resulted in a dramatic restoration of total body glycoca-
lyx 16 h later. Similar results were obtained using the LPS model
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FIGURE 5: (A) Whole-body EG volume and (B) survival of mice with the soil model of sepsis (FIP) with and without treatment with
sulodexide. *P< 0.05. FIP, fecal-induced peritonitis; SDX, sulodexide; OGT, heparanase inhibitor OGT 2115.
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|of sepsis. This accelerated restoration of EG was associated
with the amelioration of increased vascular permeability meas-
ured in pulmonary and peritoneal vascular beds. Additionally,
our AFM nanoindentation data [61] confirmed that treatment
of the damaged EG with sulodexide restored the thickness
of EG.
To evaluate the end effect of improved restoration of EG on
survival, we video-monitored animal activity in cages and
derived survival curves. There was a remarkable improvement
in survival of septic mice treated with 40mg/kg sulodexide com-
pared with vehicle [hazard ratio 0.11 (95% confidence interval)
0.02–0.59; P ¼ 0.015] as judged by Kaplan–Meyer survival
curves (Figure 5). This effect was not secondary to any interfer-
ence with the growth or virulence of bacterial flora, but was
accompanied by the improved glycocalyx of neutrophils (not
shown). This latter finding is in accord with the previously dem-
onstrated interaction between the glycocalyx of endothelial cells
and erythrocytes when one of these cellular partners has lost
glycocalyx integrity [62]. The glycocalyx in neutrophils is lost in
septic mice and, similar to the findings in endothelial cells, sulo-
dexide treatment facilitates its restoration. These findings raise
the possibility that damaged EG affects the glycocalyx of all cir-
culating formed elements. This would result in the increased
egress of leukocytes, as well as hemolysis and dysmorphic
changes in erythrocytes, both phenomena actually observed in
severe sepsis.
CONCLUSIONS
In summary, focusing on the integrity of EG, we set out to eluci-
date several tacit points related to the initiation and mainte-
nance of sepsis, sepsis-associated renal failure or contributory to
other renal diseases. We have provided evidence buttressed by
the STORM-acquired images that implicates exocytosis of
lysosome-related organelles in the very early occurring (within
minutes) crater-like patchy loss of EG at the sites of release of
their cargo. Parenthetically, considering the constitutive physio-
logical exocytosis of these organelles, clearly EG is being perpet-
ually remodeled. The distinction from sepsis, however, consists
of the ongoing oxidant stress and pro-inflammatory environ-
ment leading to the spike in exocytosis and EG degradation. An
intermediate of nitric oxide synthesis, NG-hydroxy-l-arginine,
is able to contain exocytosis and ameliorate EG degradation in
sepsis. This alone is accompanied by the improved survival of
mice with lethal sepsis. The second EG-related issue, namely,
therapeutic acceleration of its recovery after a massive degrada-
tion, was addressed here using a compound, sulodexide, that is
clinically approved for human use. It has been previously used
to restore EG in diabetic nephropathy with variable success. In
the case of severe sepsis, however, we observe accelerated resto-
ration in the whole-body EG volume and a remarkable
improvement in the animals’ survival after administration of
sulodexide. These two subjects may not only have a broader dis-
ease applicability, but they also provide additional evidence to
buttress the idea of the importance of EG and its maintenance
and repair in the prevention and treatment of vascular compli-
cations of renal and nonrenal diseases. Specifically, studies of
EG and endothelial dysfunction prompt us to speculate on the
progressive nature of both, when they coexist: damage to EG
leads to uncoupling of endothelial nitric oxide synthase and a
reduction in bioavailable nitric oxide with development or
aggravation of endothelial dysfunction, which in turn provides
a positive feedback to continuing degradation of EG, as depicted
in Figure 6. This speculative sequence has significant indirect
support, which surely will be expanded in the years to come.
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FIGURE 6: A hypothetical view of the events linking and perpetuating the pathology of EG and endothelial dysfunction.
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